Phaseline

Targets › GHRHR

GHRHR (Growth hormone-releasing hormone receptor): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Gastroenterology, Infectious disease; next expected readout Feb 2027.

Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion. (UniProt, Q02643)

Open in Phaseline: the race on GHRHR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hudson BiotechTesamorelin
Growth hormone-releasing hormone receptor agonist
GHRHRPhase 2Metabolic Associated Steatotic Liver Disease; HIV-1-infectionFeb 2027

Conditions

Metabolic Associated Steatotic Liver Disease (1) HIV-1-infection (1)

Modalities

small molecule (1)

Companies

Hudson Biotech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.